Evidence map›Paper›PMID 36552894›Full record

ArticleCells2022

Redox Genetic Risk Score and the Incidence of End-Stage Kidney Disease in People with Type 1 Diabetes.

Kamel Mohammedi, Michel Marre, Samy Hadjadj, Louis Potier, Gilberto Velho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Kamel MohammediCentre Hospitalier de Bordeaux, Department of Endocrinology, Diabetes and Nutrition, University Hospital of Bordeaux, 33604 Pessac, France.ORCID 0000-0001-6139-1197
Michel MarreInstitut Necker-Enfants Malades, INSERM, Université de Paris, 75013 Paris, France.ORCID 0000-0002-3071-1837
Samy HadjadjInstitut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, 44109 Nantes, France.
Louis PotierInstitut Necker-Enfants Malades, INSERM, Université de Paris, 75013 Paris, France.
Gilberto VelhoInstitut Necker-Enfants Malades, INSERM, Université de Paris, 75013 Paris, France.ORCID 0000-0001-8811-363X
Inserm · FRCentre National de la Recherche Scientifique · FRPopulation Health Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

End-stage kidney disease (ESKD) is a multifactorial condition influenced by genetic background, but the extent to which a genetic risk score (GRS) improves ESKD prediction is unknown. We built a redox GRS on the base of previous association studies (six polymorphisms from six redox genes) and tested its relationship with ESKD in three cohorts of people with type 1 diabetes. Among 1012 participants, ESKD (hemodialysis requirement, kidney transplantation, eGFR < 15 mL/min/1.73 m

Indexed as

Diabetes Mellitus, Type 1Kidney Failure, ChronicKidney TransplantationHumansIncidenceRisk Factorsdiabetic kidney diseaseend-stage kidney diseasegenetic risk scoreoxidative stresspolymorphismtype 1 diabetes

Identifiers

PMID36552894
PMCPMC9777489
OpenAlexW4312196592

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.